Qin et al reported a model for predicting thrombocytopenia secondary to linezolid. This can identify a patient who should be monitored more closely. The authors are from Fudan University and Zhongshan Hospital in China.
Patient selection: age >= 65 years, therapy with linezolid with platelet count > 100 * 10^9/L
Thrombocytopenia was defined as a platelet count below 100 * 10^9/L/
Parameters:
(1) age in years
(2) baseline platelet count in 10^9/L
(3) eGFR in mL per min per 1.73 sq m
(4) duration of linezolid therapy in days
(5) ICU admission
(6) concomitant therapy with piperacillin-tazobactam
Parameter
Finding
Points
age in years
< 75 years
0
>= 75 years
0.815
baseline platelet count
< 150 * 10^9/L
1.274
>= 150 * 10^9/L
0
eGFR
>= 60
0
< 60
0.937
duration of linezolid
< 10 days
0
>= 10 days
1.169
ICU admission
no
0
yes
0.987
therapy with piperacillin-tazobactam
no
0
yes
1.352
value of X =
= SUM(points for all of the parameters) - 3.720
probability of thrombocytopenia =
= 1 / (1 + EXP((-1) * X))
Performance:
• The area under the ROC curve was 0.8 in the training and 0.85 in the validation cohorts.
To read more or access our algorithms and calculators, please log in or register.
